Indigo Biosciences clearly demonstrated an investor value proposition that caught the attention of the majority of the angel investors in attendance and many of our members have indicated that they will be investing in the Company as well.
STATE COLLEGE, Pa. (PRWEB) November 06, 2017
INDIGO Biosciences, Inc. is pleased to announce that it was awarded the Stephen M. Goodman Most Valued Company Award at the Keiretsu Forum Angel Capital Expo. The Expo took place October 19, 2017 at the Union League in Philadelphia, PA. INDIGO was among twelve companies to present to an angel investor group of over 150 attendees. As part of the presentation, each investor is given three votes toward the best company at the Expo, with the winner receiving a $100,000 investment. Each company selected to present is one of the best in their field, and in the end, INDIGO Biosciences was honored to be selected as the Stephen M. Goodman award winner.
“Being selected as the Stephen M Goodman award winner by the attendees of the Keiretsu Forum Expo is an honor. All twelve companies that participated in the event represented the best in their field. This recognition demonstrates INDIGO Biosciences commitment to excellence,” said Fred Marroni, INDIGO Biosciences President and CEO. “Mr. Goodman has developed a reputation for grooming promising entrepreneurs. To be recognized with an award that carries his name is a privilege.”
The Keiretsu Forum’s Angel Capital Expo is designed to foster collaboration among various angel groups and the larger investment community, and quickly became a premier gathering of the angel capital community. Now in its 5th year, this signature event provides a large group of investors access to high-quality, diverse investment opportunities in the life sciences, healthcare, technology, energy/green technology, and other high growth investment areas.
“Keiretsu Forum Mid-Atlantic prides itself in selecting the top 12 of 60+ companies annually to participate at our annual Angel Capital Expo and the competition is fierce. Indigo Biosciences clearly demonstrated an investor value proposition that caught the attention of the majority of the angel investors in attendance and many of our members have indicated that they will be investing in the Company as well,” said Howard Lubert, Keiretsu Forum Mid-Atlantic’s Area President.
Keiretsu Forum is the world’s largest and most successful accredited private equity investor community. The Forum has nearly 2500 accredited angel investor members throughout its 52 chapters on three continents. Since Keiretsu Forum’s founding in 2000, members have invested more than $850 million in more than 750 companies.
About INDIGO Biosciences, Inc.
INDIGO Biosciences was founded in 2005 in State College, Pennsylvania, and has established itself as the industry-leading provider of both products and services focused on nuclear receptors. INDIGO offers both screening services and assay kits for the pharmaceutical, biotechnology, agri-business, and nutriceutical industries, as well as government research agencies and academic researchers. Learn more at http://www.indigobiosciences.com.
About Keiretsu Forum
Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 52 chapters on 3 continents. Keiretsu Forum members invest in highquality, diverse investment opportunities. Learn more at: http://www.KeiretsuForum-MidAtlantic.com/